TrialGut2016

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

Kazunari Murakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.